Literature DB >> 12217338

Established T(H1) granulomatous responses induced by active Mycobacterium avium infection switch to T(H2) following challenge with Schistosoma mansoni.

Randy Sacco1, Michael Hagen, Matyas Sandor, Joel V Weinstock, Richard G Lynch.   

Abstract

Mycobacterium avium established a systemic infection with granulomatous inflammation in mice. Mice chronically infected with M. avium and subsequently co-infected with Schistosoma mansoni developed additional, but morphologically distinct, hepatic granulomas. Schistosome eggs were not deposited in the spleen, and splenic granulomas in co-infected mice contained mycobacteria. In complete contrast to the T(H1) cytokine pattern observed with granuloma lymphocytes from M. avium-infected mice, granuloma lymphocytes from co-infected mice stimulated with PPD elaborated IL-4, but not IFN-gamma. Furthermore, mycobacterial granulomas in concurrently infected mice contained large numbers of eosinophils, a feature never seen in granulomas of M. avium-infected mice. Serum IgG1 and IgE levels in concurrently infected mice were significantly higher, but IgG2a levels significantly lower, than those in M. avium-infected mice, further evidence that the T(H1) component induced by M. avium is modulated subsequent to co-infection with S. mansoni. The dominance of the T(H2) response observed in this model could have clinical implications in areas where parasites and mycobacteria co-exist.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12217338     DOI: 10.1006/clim.2002.5263

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  13 in total

1.  Helminths and harmony.

Authors:  J V Weinstock; R Summers; D E Elliott
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

2.  Adjuvant modulation of the cytokine balance in Mycobacterium tuberculosis subunit vaccines; immunity, pathology and protection.

Authors:  Else Marie Agger; Joseph P Cassidy; Joseph Brady; Karen S Korsholm; Carina Vingsbo-Lundberg; Peter Andersen
Journal:  Immunology       Date:  2008-01-12       Impact factor: 7.397

Review 3.  Role of helminths in regulating mucosal inflammation.

Authors:  Joel V Weinstock; Robert W Summers; David E Elliott
Journal:  Springer Semin Immunopathol       Date:  2005-06-15

Review 4.  Helminth-Tuberculosis Co-infection: An Immunologic Perspective.

Authors:  Subash Babu; Thomas B Nutman
Journal:  Trends Immunol       Date:  2016-08-05       Impact factor: 16.687

5.  Human type 1 and 17 responses in latent tuberculosis are modulated by coincident filarial infection through cytotoxic T lymphocyte antigen-4 and programmed death-1.

Authors:  Subash Babu; Sajid Q Bhat; N Pavan Kumar; S Jayantasri; S Rukmani; Paul Kumaran; P G Gopi; C Kolappan; V Kumaraswami; Thomas B Nutman
Journal:  J Infect Dis       Date:  2009-07-15       Impact factor: 5.226

Review 6.  Effect of helminth-induced immunity on infections with microbial pathogens.

Authors:  Padmini Salgame; George S Yap; William C Gause
Journal:  Nat Immunol       Date:  2013-11       Impact factor: 25.606

Review 7.  Translatability of helminth therapy in inflammatory bowel diseases.

Authors:  Joel V Weinstock; David E Elliott
Journal:  Int J Parasitol       Date:  2012-11-21       Impact factor: 3.981

8.  Role of T cell TGF-beta signaling in intestinal cytokine responses and helminthic immune modulation.

Authors:  M Nedim Ince; David E Elliott; Tommy Setiawan; Ahmed Metwali; Arthur Blum; Hung-lin Chen; Joseph F Urban; Richard A Flavell; Joel V Weinstock
Journal:  Eur J Immunol       Date:  2009-07       Impact factor: 5.532

Review 9.  Immunological mechanisms by which concomitant helminth infections predispose to the development of human tuberculosis.

Authors:  Patricia Méndez-Samperio
Journal:  Korean J Parasitol       Date:  2012-11-26       Impact factor: 1.341

10.  Chronic schistosome infection leads to modulation of granuloma formation and systemic immune suppression.

Authors:  Steven K Lundy; Nicholas W Lukacs
Journal:  Front Immunol       Date:  2013-02-20       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.